Background: The Krebs von den lungen-6 (KL-6), which is mainly expressed by type II cells, is associated with the prognosis and severity of the diameter pulmonary disease (ILD). This research has attempted to investigate the relationship between KL-6 concentrations and the presence of ILD against lung abnormalities (ILA).
Methods: This retrospective study of a central center included 147 patients suspected of ILD and underwent KL-6 tests between October 2022 and March 2023. Epidemiological and clinical details of patients, including the effects of pulmonary function tests and computing findings.
Results: The average age within the cova was 77.1 years, with 97.3% (143 patients) being men. Specifically, the ILA team showed significantly reduced KL-6 levels compared to the ILD team (411.6 ± 298.8 against. 968.8 ± 901.9 U/ml, p <0.001). Using a 410 U/ml limit for KL-6, the diagnostic performance yielded an area below the curve (95% CI) 0.727 (0.605-0,849), proving 80.8% sensitivity and 64.7% specialty.
Conclusions: Our findings show that KL-6 serum concentrations are significantly increased in patients with clinically recognized and cured ILD compared to those specified with ILA. In addition, the association between higher levels of KL-6 and a reduced percentage of forced vital capacity highlights the biomarker’s potential in differentiation between ILD that requires intervention and less serious abnormalities.
Basic findings
• Serum levels Krebs von den lungen-6 (KL-6) are significantly increased in patients with interstitial pulmonary disease (OLD) compared to those with interstitial lung abnormalities (ILA), indicating its potential as a diagnostic biological index.
What is well known and what’s new?
• KL-6 is mainly expressed by type II cells and is associated with the prognosis and severity of ILD.
• The study provides evidence that KL-6 serum concentrations are significantly increased in clinically recognized and processed ILD compared to ILA. It also points to the relationship between KL-6 levels and pulmonary function, especially forced vital.
What is the impact and what needs to change now?
• Clinical doctors could consider the possibility of integrating KL-6 evaluations into the diagnostic process for patients with a suspected ILD to improve early detection and management strategies. Further research may be justified in creating standard protocols for KL-6 tests in clinical arrangements.
Source:
Magazine report:
Song. Jh, et al. (2025). Krebs von den lungen-6 as a biomarker to distinguish between intermediate lungs and intermediate pulmonary abnormalities based on computed tomography findings. Thoracic newspaper. Doi.org/10.21037/JTD-24-1833.
